Today: 23 January 2026
Subscribe
Browse Category

Investment News 19 June 2025 - 21 June 2025

Poland Real Estate Market 2025: Trends, Prices, Yields and Outlook

Poland Real Estate Market 2025: Trends, Prices, Yields and Outlook

In 2024 Poland’s commercial property investment volume exceeded €5 billion, rising about 142% year-on-year. In May 2025, the National Bank of Poland cut the reference rate to 5.25%, the first reduction since 2023. Bezpieczny Kredyt 2% boosted home loans in 2024 to PLN 83.9 billion, up 43.2% from 2023. In Q1 2025, Warsaw resale housing averaged 16,459 PLN/m² (+8.1% YoY)…
21 June 2025
··
Warsaw Real Estate Market 2025 –Comprehensive Report

Warsaw Real Estate Market 2025 –Comprehensive Report

In 2024 Poland’s total commercial property investment was about €4.5–5.0 billion, more than double 2023. Warsaw generates about 24% of Poland’s national GDP, underscoring its role as the country’s economic engine. Foreign capital dominated 2024’s commercial acquisitions, accounting for over 90% of investment. In Q1 2025, Warsaw’s average apartment price was around PLN 16,400 per m², roughly €3,500–€4,000 per m²,…
20 June 2025
···
Quantix Prime AI Review 2025: Is This “Autopilot” Trading Bot a Goldmine or an Expensive Scam? Read This Before You Invest

Quantix Prime AI Review 2025: Is This “Autopilot” Trading Bot a Goldmine or an Expensive Scam? Read This Before You Invest

Quantix Prime AI is a web-based automated trading platform that acts as a marketing platform connecting users to partner brokers, with trading accounts and funds actually held by the brokers. It claims to use advanced AI algorithms that scan real-time price feeds, historical charts, news and social sentiment to identify profitable trades and operate 24/7. The platform advertises multi-asset support—primarily…
19 June 2025
·
1 … 166 167 168

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Go toTop